BSX vs. MDLN: Boston Scientific vs. Medline Stock Comparison

Company Profile

Boston Scientific (BSX) and Medline (MDLN) both belong to the Health Care Equipment & Supplies industry, though BSX is classified under Health Care Equipment while MDLN falls under Health Care Supplies.

Boston Scientific (BSX) has been public since May 19, 1992, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Boston Scientific (BSX) has a non-negative beta of 0.57.

Risk-Adjusted Performance

Risk-Return Positioning

Both BSX and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Boston Scientific (BSX) at 14.12% and Medline (MDLN) at 4.85% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Boston Scientific (BSX) at 16.62% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

Boston Scientific (BSX) at 19.05% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Boston Scientific (BSX) reports revenue growth of 19.87%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Both companies show strong earnings momentum, but Medline (MDLN) at 117.38% is the standout with EPS growth above its industry range; Boston Scientific (BSX) at 55.20% also sits in the top quartile.

Growth Metrics

Financial Strength

Medline (MDLN) at 4.04 carries current ratio above its industry’s typical mid-range, while Boston Scientific (BSX) at 1.37 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both Boston Scientific (BSX) at 0.46 and Medline (MDLN) at 0.65 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Boston Scientific (BSX) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Boston Scientific (BSX) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Boston Scientific (BSX) at 18.04 sits in the cheaper P/E ratio quartile, while Medline (MDLN) at 90.09 trades above its peer range — a wide earnings-valuation gap relative to industry peers.

On P/S ratio, both Boston Scientific (BSX) at 2.94 and Medline (MDLN) at 1.70 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Boston Scientific (BSX) at 2.42 and Medline (MDLN) at 2.95 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics